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The aim of the present study was to investigate the clinical and morphological features of nonspecific invasive breast cancer according 
to its molecular subtypes. Materials and Methods: 163 women with nonspecific invasive breast cancer (T1–4N0–3M0) were in-
cluded in the present study. Luminal A type of breast cancer was detected in 101 women, luminal B type — in 23 women, overexpres-
sion of HER2/neu was identified in 14 women and triple-negative cancer — in 25 women. Results: The study revealed that various 
molecular subtypes of breast cancer differ in the morphological structure, the expression characteristics of the primary tumor and the 
rate of lymphogenous and hematogenous metastasis. Lymphogenous metastases were more frequently (in 71%) detected in HER2/neu 
overexpressing breast cancer than in luminal A (41%), luminal B (39%) and triple-negative tumors (40%). Hematogenous metastasis 
did not depend on the morphological structure of carcinoma infiltrative component, the state of tumor stroma as well as the prolifera-
tive activity in all the investigated groups. Conclusion: The revealed clinicopathological characteristics of different molecular subtypes 
of invasive breast cancer allow to predict the possible outcome of the disease and select personalized treatment strategy for patients 
more reasonably.
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In recent years the molecular genetic classifica-
tion of breast tumors offered by C.M. Perou et al. 
(2000) is used to determine appropriate treatment for 
patients on an individual basis [1]. This classification 
is based on cluster analysis of 465 genes and enables 
to differentiate between the following breast cancer 
subtypes: luminal A, luminal B, HER2/neu-positive 
overexpression and triple-negative. Each molecular 
genetic subtype is associated with specific molecular 
and clinical signs and is characterized by features of tu-
mor response to chemotherapy, metastatic behavior 
and different outcomes [2, 3].
Luminal A tumors are highly sensitive to hormone 
therapy, have low risk of recurrence and high survival 
rates [2, 4, 5]. Luminal B tumors in comparison with 
luminal A ones are often accompanied by metastases 
in lymph nodes and recurrence risk. These tumors are 
usually not sensitive to chemotherapy and hormone 
therapy, but they are sensitive to trastuzumab in cases 
with positive HER2/neu expression [6, 7].
HER2/neu-positive breast cancer is characterized 
by the large size of the primary tumor, frequent involve-
ment of lymph nodes in the metastatic process and 
low survival rates. HER2/neu-positive tumors are not 
sensitive to hormone therapy, however administration 
of trastuzumab in the adjuvant setting is effective for 
them [6–8].
Triple-negative cancer is found among younger 
women and is often associated with BRCA1 mutations. 
Low differentiation grade, necrosis and inflamma-
tory infiltration in the tumor stroma characterize the 
histological structure of this cancer subtype. These 
tumors have big size, they often metastasize to lymph 
nodes and distant organs and have lower survival rates. 
Triple-negative tumors are sensitive to anthracycline-
taxane-based chemotherapy [9, 10].
Classification of breast cancers described above 
is still relevant. Evaluation of estrogen receptors (ER), 
progesterone receptors (PR), HER2/neu and Ki-67 ex-
pression is considered to be the gold standard in im-
munohistochemical diagnosis of breast cancer. In ca-
ses of triple-negative cancer cytokeratins CK5/6 and 
epidermal growth factor receptor 1 or vimentin are 
further detected. Knowledge of this biomarker status 
enables to determine therapeutic schemes for breast 
cancer patients [6, 7, 11, 12]. However, using this 
biomarker panel in some cases leads to considerable 
difficulties in interpretation of immunohistochemical 
reactions. It may be explained by tumor heterogene-
ity, which underlies simultaneous detection of luminal 
and basal signs. It is also the reason for distinguishing 
the so-called “basal-and-luminal” tumors which are 
considered to have cell clones responding to treat-
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ment differently. This expression peculiarity deserves 
special attention [13].
In addition, detailed analysis of tumor morphologi-
cal structure in different molecular subtypes of breast 
cancer is required. Recent data regarding this issue 
are scarce and are limited to identification of tumor 
histological variant and differentiation grade only.
The aim of the present study was to investigate the 
clinical and morphological features of nonspecific inva-
sive breast cancer according to its molecular subtypes.
MATERIALS AND METHODS
Patients. 163 women (mean age — 55.9 ± 
11.1 years) with nonspecific invasive breast cancer T1–
4N0–3M0, who were treated in General Oncology De-
partment of Tomsk Cancer Research Institute (Tomsk, 
Russia) from January 1999 to January 2007, were 
included in the present study (Table 1). 
Table 1. Clinicopathological characteristics of breast cancer patients
Characteristics
Tumorsubtype
Luminal A, %
(n = 101)
Luminal B, %
(n = 23)
Triple-nega-
tive, % 
 (n = 14)
HER2/neu-
positive, %  
(n = 25)
Mean age, years 55.9 ± 10.5 53.4 ± 12.1 59.1 ± 11.7 53.7 ± 12.3
Menopausal sta-
tus
66 65 76 64
Tumor localization
Outer quadrants 54 71 63 60
Internal quad-
rants
46 29 37 40
ER
Positive 9 87 0 0
Negative 91 13 100 100
PR
Positive 11 74 0 0
Negative 89 26 100 100
HER2
Positive 0 0 0 100
Negative 100 100 100 0
Ki-67
Expression ≥20% 0 100 52 50
Expression <20% 100 0 48 50
Tumor stage
0 0 0 0 0
I 33 22 4 0
II 54 65 80 64
III 9 13 16 36
IV 4 0 0 0
Tumor size (cm)
T1 (< 2) 52 43 12 14
T2 (2–5) 40 52 84 64
T3 (> 5) 8 5 4 22
Node status
N0 59 61 60 29
N1 24 26 8 43
N2 11 7 20 7
N3 6 6 12 21
Lymph node involvement
Positive 41 39 40 71
Negative 59 61 60 29
Histological grade
Low grade  
(I and II)
98 91 96 86
High grade (III) 2 9 4 14
The study was approved by the Local Medical  Ethics 
Committee, and informed consents were obtained 
from all the patients prior to analysis. The patients did 
not receive preoperative treatment. 99 (61%) patients 
went through radical mastectomy, and 64 (39%) women 
underwent sectoral resection of breast cancer with axil-
lary lymph node dissection. In the postoperative period 
122 women received adjuvant chemotherapy schemes 
CMF (cyclophosphamide + methotrexate + fluorouracil), 
FAC (fluorouracil + doxorubicin + cyclophosphamide), 
CAX (cyclophosphamide + doxorubicin + capecitabine). 
Antiestrogen therapy with tamoxifen was prescribed 
for 41 postmenopausal women. Postoperatively 40 pa-
tients were treated with remote gamma-therapy on the 
postope rative scar and/or regional lymph outflow zones 
in the standard mode. The period of patient monitoring 
was from 5 to 10 years.
Methods. Morphological examination of the surgi-
cal specimens was performed by the standard method 
using a light microscope “Carl Zeiss Axio Lab.A1”. 
The histological type of breast cancer was defined 
according to recommendations of the World Health 
Organization (Geneva, 2012). The study included only 
cases with nonspecific invasive carcinoma. The ma-
lignancy grading was estimated according to the 
modified Scarff — Bloom — Richardson grading sys-
tem. Previously we described the diversity of invasive 
growth patterns of tumor cells probably resulted in high 
intratumor morphological heterogeneity, which (e.g. 
in breast cancer) is represented by different morpho-
logical structures: tubular, alveolar, trabecular, solid 
structures (patterns), and discrete (small) groups 
of tumor cells [14–17].
Expression of hormone receptors and oncoproteins 
was assessed by immunohistochemistry: DAKO Clone 
1D5 was used for ER, DAKO Clone PgR 636 — for 
PR and DAKO Clone MIB-1 — for Ki-67. Expression 
of sex hormone receptors was determined by Histo-
Score. Assessment of Ki-67 was based on the percen-
tage of positive cell nuclei in each variant of paren-
chymal component structures of primary nonspecific 
invasive carcinoma, regardless of staining intensity.
HER2/neu protein overexpression was determined 
by immunohistochemistry: DAKO polyclonal rabbit 
anti-human antibodies were used for c-erB-2 (dilution 
1:500) and it was semi-quantitated based on staining 
of the cytoplasmic membrane rather than cytoplasm it-
self. HER2/neu overexpression was rated negative (0+ 
and 1+), indeterminate (2+) or positive (3+). In cases 
of 2+, women were not included in the study. The posi-
tivity cut-off value for HER2/neu was set at 30%.
For the purpose of the present study breast 
cancer was classified into four subtypes based 
on estrogens and progesterone hormone receptors, 
HER2 and  Ki-67 values: luminal A (ER+PR+HER2–, 
Ki-67 expression < 20%), luminal B (ER+PR+HER2–, 
Ki-67 expression ≥ 20%), HER2/neu-positive over-
expression (ER–PR–HER2+) and triple-negative 
(ER–PR–HER2–). Luminal A type of breast cancer was 
detected in 101 women, luminal B type — in 23 women, 
overexpression of HER2/neu — in 14 women and triple-
negative cancer — in 25 women.
The presence of metastatic lesions was assessed 
in the lymph nodes, and the number of lymph nodes 
with metastases was counted. Information about the 
frequency and timing of hematogenous metastasis was 
received from patient case histories or outpatient cards.
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Statistical analysis. Qualitative variables were 
expressed as “n” and percentage, whereas quantita-
tive variables were expressed as their mean (M) value 
and standard deviation (SD). In order to compare 
qualitative variables, the χ2-test was implemented. 
Mean values were compared using ANOVA. Statisti-
cal significance was set at p < 0.05, using two-tail 
approach. Statistical analysis was performed using 
STATISTICA 8.0 for Windows (StatSoft Inc., USA).
RESULTS
Such clinical parameters as age and menstrual 
status of women were analyzed in the present study. 
The mean age of patients with various breast cancer 
molecular subtypes did not differ (luminal A sub-
type — 55.9 ± 10.5 years, luminal B subtype — 53.4 ± 
12.1 years, triple-negative cancer — 59.1 ± 11.7 years 
and HER2/neu overexpressing tumors — 53.7 ± 
12.3 years). In all the investigated groups of patients 
menopausal status was as follows: in patients with 
luminal A subtype — in 66% of cases; with luminal 
B subtype — in 65% of cases; with triple-negative 
cancer — in 76% of cases; with HER2/neu overex-
pression — in 64% of cases. Unilateral lesion of the 
breast was detected in most cases. Tumors were more 
frequently localized in the outer quadrants (luminal 
A tumors — 54%, luminal B tumors — 71%, triple-
negative cancer — 63%, HER2/neu overexpressing tu-
mors — 60%). The detection rate of multicenter tumor 
growth did not differ in all the patient groups as well 
(luminal A — 21%, luminal B — 22%, triple-negative 
cancer — 13% HER2/neu overexpression — 21%).
Small tumors (< 2 cm in diameter) were more pre-
valent in patients with luminal cancer types, whereas 
larger tumors were typical of patients with triple-nega-
tive and HER2/neu overexpressing tumors (Fig. 1).
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Fig. 1. Tumor size in patients with various molecular breast 
cancer subtypes
The morphological examination of the primary 
tumor in most cases revealed the second grade of ma-
lignancy: in 90% of cases in luminal A breast cancer, 
in 80% of cases in luminal B subtype, in 95% of cases 
in triple-negative and in 86% of cases in HER2/neu 
overexpressing tumors. The frequency of ductal struc-
ture detection did not differ in the investigated groups.
The histological investigation of primary tumor infil-
trative component revealed a number of features spe-
cific to each molecular breast cancer subtype. It turned 
out that the infiltrative component in luminal A and 
B molecular subtypes was very diverse, all five types 
of the structures classified by us (alveolar, trabecular, 
tubular, solid and discretely spaced groups of tumor 
cells) were detected in them more often (in 13 and 22% 
of cases, respectively). In the meantime, histological 
monomorphic neoplasms were detected in triple-
nega tive and HER2/neu overexpressing tumors 
(in 16 and 14% of cases, accordingly), the infiltrative 
component in them had only one variant of structures. 
The received data demonstrate different grades of in-
tratumoral morphological heterogeneity in women with 
different breast cancer molecular subtypes (Table 2).
Table 2. Number of different structure types in the infiltrative component of non-
specific invasive carcinoma according to the molecular subtypes of breast cancer
Number of struc-
ture types in the 
infiltrative com-
ponent
Molecular subtype, n (%)
Luminal A  
(n = 101)
Luminal B  
(n = 23)
Triple-nega-
tive (n = 25)
HER2/neu-
positive  
(n = 14)
1 4/101
(4)
1/23
(4)
4/25
(16)
р1 = 0.01
р2 = 0.08
2/14
(14)
р1 = 0.05
2 17/101
(17)
4/23
(17)
6/25
(24)
4/14
(29)
3 45/101
(44)
8/23
(35)
8/25
(32)
5/14
(36)
4 22/101
(22)
5/23
(22)
6/25
(24)
3/14
(21)
5 13/101
(13)
5/23
(22)
1/25
(4)
р2 = 0.03
0/14
(0)
р1 = 0.07
р2 = 0.03
Note: p1 — compared with luminal A group; p2 — compared with luminal B group.
In patients with triple-negative and HER2/neu over-
expressing cancer the tubular structures were observed 
rarely: in 16 and 21% of cases as opposed to luminal 
A (45%; p = 0.004 and p = 0.004, accordingly) and 
in luminal B (52%; p = 0.005 and p = 0.03, accordingly) 
tumor subtypes. Our results indirectly indicate low 
differentiation grade of triple-negative and HER2/neu 
overexpressing tumors and do not conflict with data 
of other researchers about low-grade triple-negative 
cancer [18]. The other tumor structures (alveolar, tra-
becular, solid and discretely spaced groups of cells) 
were detected with approximately identical frequency.
The morphological study of the stromal tumor com-
ponent showed that stromal fibrosis with parenchymal 
component ≤ 10% did not take place in triple-negative 
tumors in contrast to luminal A (13%; p = 0.02), luminal 
B (9%; p = 0.06) and HER2/neu overexpressing (14%; 
p = 0.03) cancer subtypes. More significant inflam-
matory stroma infiltration was found in triple-negative 
breast cancer (36%) as opposed to luminal A (8%; p = 
0.0002) and luminal B (13%; p = 0.03) subtypes.
The study of tumor cell proliferative activity in different 
breast cancer molecular subtypes showed that Ki-67 ex-
pression in luminal A tumors was 2.00 (1.00–5.00)%, 
in luminal B tumors — 20.00 (2.30–21.00)%, in triple-
negative cancer subtype — 2.00 (1.00–3.00)% and 
in HER2/neu-positive tumors — 2.50 (1.50–5.15)%.
Lymphogenous metastases were more frequently 
(in 71% of cases) detected in women with HER2/neu 
overexpressing cancer subtype in comparison with 
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luminal A (41%; p = 0.01), luminal B (39%; p = 0.03) and 
triple-negative tumors (40%; p = 0.03). The number 
of metastatic lymph nodes in women with luminal A, 
luminal B and HER2/neu overexpressing tumors did 
not differ (p > 0.05). Metastatic lesion of four and more 
lymph nodes (criteria N2–3) was more often diagnosed 
in patients with triple-negative cancer subtype (Fig. 2). 
The average number of regional lymph nodes involved 
in the metastatic process did not differ among various 
molecular subtypes of breast cancer (p > 0.05).
58
67
20
60
42
33
80
40
0
20
40
60
80
100
Luminal A Luminal B Triple-negative HER2/neu-
positive
Node status
N1
N2–3
Nu
m
be
r o
f p
at
ie
nt
s,
 %
Fig. 2. Nodal metastasis rate in women with various molecular 
breast cancer subtypes. p1 = 0.01 — compared with lumi-
nal A group; p2 = 0.03 — compared with luminal B group; p3 = 
0.04 — compared with HER2/neu-positive group
There was no relation between the lymphogenous 
metastatic process and patient’s age. The rate of lym-
phogenous metastasis was studied in various molecu-
lar breast cancer subtypes in the groups of women 
with different menstrual status. It was revealed that 
lymphogenous metastases did not occur (0%) in the 
investigated patients with luminal B subtype and intact 
menstrual function, while in postmenopausal women 
it was detected in 60% of cases (p = 0.005).
Research of lymphogenous metastatic features 
depending on the morphological structure of primary 
tumor tissue was carried out. Among patients with 
luminal A and luminal B subtypes, lymphogenous me-
tastases were more prevalent in cases with more varied 
morphological tumor constitution, which infiltrative com-
ponent consisted of three or more different structure 
types. Such regularity was not observed in triple-nega-
tive and HER2/neu overexpressing tumors (Table 3).
Table 3. Lymphogenous metastasis rate in patients with various molecu-
lar breast cancer subtypes according to the number of different structure 
types in the infiltrative tumor component
Number of struc-
ture types in the 
infiltrative com-
ponent
Molecular subtype, n (%)
Luminal A  
(n = 101)
Luminal B  
(n = 23)
Triple-nega-
tive (n = 25)
HER2/neu-
positive  
(n = 14)
1 0/41 (0) 0/9 (0) 1/10 (10) 1/10 (10)
2 3/41 (7) 0/9 (0) 3/10 (30) 3/10 (30)
3 21/41 (51)
р1 < 0.001
р2 < 0.001
3/9 (33)
р1 = 0.03
р2 = 0.03
4/10 (40) 3/10 (30)
4–5 17/41 (42)
р1 < 0.001
р2 < 0.001
6/9 (67)
р1 = 0.004
р2 = 0.004
2/10 (20) 3/10 (30)
Note: p1 — compared with patients with one structure type in the infiltrative 
component; p2 — compared with patients with two structure types in the in-
filtrative component.
No significant distinctions in the incidence of hema-
togenous metastasis depending on patients’ age, men-
strual status, size and grade of tumors were revealed 
(p > 0.05) in any molecular breast cancer subtype.
Hematogenous metastasis did not depend on the 
morphological structure of the carcinoma infiltrative 
component, the state of tumor stroma as well as the 
proliferative activity in all the investigated groups. 
In women with luminal cancer subtypes the probability 
of hematogenous metastasis was not associated with 
any percentage of ER+- and PR+-cells or ER and PR ex-
pression index (on the Histo-Score scale).
The dependence of distant metastasis on status 
of regional lymph nodes was found only in patients with 
triple-negative breast cancer: all women with tumor 
lymph node lesion had hematogenous dissemination 
process (χ2 = 9.3; p = 0.002) at various stages of moni-
toring. Such regularity was not observed in other 
breast cancer subtypes (Fig. 3).
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Fig. 3. Hematogenous dissemination rate according to the 
pre sence of lymph node metastases in women with various 
molecular breast cancer subtypes; p = 0.002 — compared with 
triple-negative patients with N0 node status
DISCUSSION
The present study revealed that various molecular 
subtypes of breast cancer differ in the morphological 
structure, the expression profile of the primary tumor 
and the rate of lymphogenous and hematogenous 
metastasis. It should be emphasized that these diffe-
rences are found within one nosological form of non-
specific invasive breast cancer (ICD-O code 8500/3).
In our opinion one important distinction between 
the molecular subtypes of breast cancer is the promi-
nence of morphological heterogeneity. According 
to our research, phenotypic drift takes place in non-
specific invasive cancer. It consists in the increase 
in time of various types of breast cancer infiltrative 
component structures. It turned out that luminal sub-
types were often characterized by the most prominent 
heterogeneity. At the same time in triple-negative and 
HER2/neu overexpressing tumors the cases with one 
type of infiltrative component structures prevailed [15].
It appears that the tumor is growing faster in triple-
negative and HER2/neu positive breast cancers than 
in the luminal subtypes: a series of indirect signs indi-
cate it. Cases with one variant of infiltrative component 
structures are more common in triple-negative and 
HER2/neu positive breast cancers than in the luminal 
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subtypes. The combination of minimal morphological 
structure heterogeneity with greater tumor size and 
greater parenchymal component volume in triple-
negative cancer can be taken as an argument in favor 
of accelerated tumor growth in this subtype in com-
parison with the luminal ones.
Significant distinctions between various molecu-
lar breast cancer subtypes related to lymphogenous 
metastasis. In luminal subtypes of breast cancer, lym-
phogenous metastases were more frequent at higher 
morphological tumor heterogeneity. Apparently, higher 
morphological tumor heterogeneity, reflecting pheno-
typic diversity of tumor elements, makes emergence 
of a cell clone with lymphatic metastasis capacity 
more probable.
It was found that in patients with luminal B sub-
type the rate of lymphogenous metastases depends 
on the menstrual status being significantly higher 
in menopausal women. We have previously shown that 
invasive ductal breast carcinoma in women older than 
35 years with intact menstrual function has significant 
clinicopathological and molecular genetic features 
as opposed to menopausal patients [19].
Triple-negative invasive breast cancer particularly 
differs in the parameters of lymphogenous metastasis. 
The lesions of four or more lymph nodes are mostly 
diagnosed exactly in these patients. The interest 
in studying lymphogenous metastatic mechanisms 
does not fade away. The search for the informative 
parameters of this process associated with the overall 
survival rate continues. It was agreed that an unfavo-
rable prognostic sign is high percentage of lymph node 
lesions [20, 21]. However, until now the causes and 
the mechanisms of involvement of different number 
of lymph nodes in the metastatic process are unknown.
The prediction of the likelihood of axillary lymph 
node metastatic lesions in breast cancer in cases where 
sentinel lymph node is affected with metastases is a dif-
ficult problem. This problem has not been solved despite 
creation of several nomogram variants aiming to predict 
the lesion of non-sentry lymph nodes upon metastasis 
detection in the sentinel node [22, 23]. In this regard, the 
regular involvement of a large number of lymph nodes 
in the metastatic process in some patients with triple-
negative breast cancer may be a promising model sys-
tem for studying widespread lymphogenous metastasis.
Another feature of triple-negative breast cancer 
is obvious relation between lymphogenous and hema-
togenous metastasis. Hematogenous dissemination 
was detected in all cases with lymph node meta-
static lesion only in this molecular subtype. For other 
molecular subtypes of breast cancer the possibility 
of hematogenous metastasis did not depend on the 
presence of lymphogenous metastasis.
The explanation of these distinctions may be found 
in S. Paget’ “Seed and Soil” concept [24]. It can 
be suggested that the emergence of tumor cell clones 
with the ability to metastasize (“seed”) in triple-
negative breast cancer subtype coincides with the 
formation of optimal cellular and molecular microen-
vironment in the regions of hematogenous metastasis 
development (“soil”). Moreover, tumor cells are ca-
pable of adapting not only to the premetastatic niches 
in the regional lymph nodes, but, probably, to the areas 
of hematogenous metastases formation as well.
Apparently, triple-negative nonspecific invasive 
breast cancer may be a suitable model for studying 
the link between lymphogenous and hematogenous 
metastasis. The environment for emergence of “seed” 
and “soil” has more independent nature in luminal 
and HER2/neu positive breast tumors than in triple-
negative cancer subtype.
Thus, different molecular genetic subtypes of breast 
cancer are characterized by significant morphologi-
cal diversity and severity of intratumor morphological 
heterogeneity, which may be associated with regularity 
of lymphogenous and hematogenous metastasis.
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